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Abstract
The present study examined whether pre-injury administration of morphine can prevent partial
sciatic nerve injury-induced neuropathic pain in mice. We observed that pre-injury administration
of subcutaneous (s.c.) and intracerebroventricular (i.c.v.) morphine dose-dependently prevented
the development of both thermal and mechanical hyperalgesia at 7 days following nerve injury in
mice. The pre-injury morphine (s.c.)-induced analgesia was significantly blocked by pretreatment
with naloxone injected s.c. or i.c.v., but not i.t., suggesting that systemic morphine produced the
pre-emptying effects mainly by acting at the supra-spinal sites. Since it is believed that activation of
descending monoaminergic mechanisms in spinal cord largely contributes to the supra-spinal
analgesic effects of morphine, we investigated the involvement of serotonergic and noradrenergic
mechanisms in spinal cord in the pre-injury morphine-induced analgesic effects. We found that pre-
injury s.c. morphine-induced analgesic effect was significantly blocked by i.t. pretreatment with
serotonergic antagonist, methysergide and noradrenergic antagonist, phentolamine. In addition,
pre-injury i.t. injection of serotonin uptake inhibitor, fluoxetine and α 2-adrenergic agonist,
clonidine significantly prevented the neuropathic hyperalgesia. We next examined whether pre-
injury morphine prevented the expression of neuronal hyperactivity markers such as c-Fos and
protein kinase C γ  (PKCγ ) in the spinal dorsal horn. We found that pre-injury administration of s.c.
morphine prevented increased expressions of both c-Fos and PKCγ  observed following nerve
injury. Similar results were obtained with i.t. fluoxetine and clonidine. Altogether these results
suggest that pre-injury administration of morphine might prevent the development of neuropathic
pain through activation of descending monoaminergic pain inhibitory pathways.
Background
One of the critical factors that initiate and maintain
chronic pain is central sensitization where neurons in the
spinal dorsal horn become more excitable due to prior
repetitive noxious stimuli [1]. Thus, preventing the initial
cascade of neural events may eliminate the long-term
hypersensitivity. Initiating an analgesic regimen before
onset of such noxious stimulus in an attempt to prevent
the central sensitization is known as preemptive analgesia
[2]. The concept of preemptive analgesia was originally
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proposed at the beginning of the last century by Crile [3].
Since the revival of the concept again by Woolf in 1983 in
experimental animals [4], it has been practiced in the
clinic in order to lessen post-operative pain following var-
ious surgical operations [2,5-8]. In spite of some contro-
versies regarding the effectiveness of preemptive analgesia
in some clinical settings, it may have tremendous eco-
nomic benefits due to savings from reduced length of hos-
pital stay, fewer post-operative complications, and
improved quality of life [9]. Preemptive analgesia strate-
gies mainly include infiltration with local anesthetics,
nerve block, epidural block, use of analgesics such as mor-
phine, NSAIDS, cyclooxygenase (COX)-2 inhibitors, inhi-
bition of pain pathways by NMDA antagonists etc. [2,7-
9].
Both clinical and preclinical studies suggest that pre-oper-
ative administration of morphine and other opioid anal-
gesics can improve post-operative pain management [10-
12]. Recent studies also demonstrate that opioids are able
to prevent central sensitization in animal models of pain
[13]. However, the effectiveness of pre-injury morphine to
prevent induction of nerve injury-induced neuropathic
pain has been largely unknown. Smith et al., [14] reported
that pre-injury administration of systemic morphine was
less effective than α 2-adrenergic receptor agonist, cloni-
dine in preventing the mechanical hyperalgesia in a rat
model of mononeuropathy. On the other hand, Puke and
Wiesenfeld-Hallin [15] showed that pre-operative intrath-
ecal administration of morphine, but not clonidine, pre-
vented the autotomy behavior in a rat peripheral axotomy
model. Therefore the exact mechanism of preemptive
analgesic effect of morphine in nerve injury-induced pain
is yet to be clarified. It is well known that µ-opioid recep-
tors (MOP) are largely distributed in different brain areas
with some distribution in the spinal dorsal horn and dor-
sal root ganglion neurons [16]. The analgesic effect of sys-
temic morphine is, however, mainly produced by
activation of MOP in the periaqueductal grey (PAG), and
brainstem nucleus raphe magnus (NRM) and locus coer-
uleous (LC), ultimately activating the descending pain
inhibitory pathways consisting mainly of the noradrener-
gic and serotonergic neuronal terminals to the spinal cord
[17]. Direct activation of the spinal MOP by intrathecal
morphine is also reported to produce potent acute analge-
sia in experimental animals [18,19]. However, the efficacy
of both systemic and spinal morphine is reduced in neu-
ropathic pain [19,20]. Therefore, the concept of pre-oper-
ative application of morphine could provide a way out to
circumvent the limitations associated with acute adminis-
tration of morphine against such painful conditions.
In the present study, we utilized a systematic approach to
see the exact contribution of supra-spinal and spinal µ-
opioid receptors in the pre-injury morphine-induced
analgesic effects by administering it through various
routes. We also examined the contribution of spinal
monoaminergic systems in the pre-injury morphine-
induced analgesic effects. In addition, we observed the
effects of pre-injury administration of morphine on nerve
injury-induced increases in expression of c-Fos and PKCγ ,
two important markers of neuronal hyperactivity, in the
spinal cord.
Results
Pre-, but not post-, injury administration of morphine 
prevented the development of thermal and mechanical 
hyperalgesia in nerve-injured mice
Morphine, injected subcutaneously (s.c.) 30 min before
partial sciatic nerve injury in mice, dose-dependently pre-
vented the development of both thermal and mechanical
hyperalgesia observed at 7 days after nerve injury with a
significant effect at doses of 3 and 10 mg/kg s.c. (Fig.
1A,D). However, 10 mg/kg of s.c. morphine, injected 30
min after the nerve injury operation, failed to prevent the
development of thermal or mechanical hyperalgesia in
mice (Fig. 1A,D; last column). The pre-emptying effects of
pre-injury morphine on post-injury pain continued at day
14 after nerve injury (data not shown). When we exam-
ined the effect of pre-injury intrathecal (i.t.) and intracer-
ebroventricular (i.c.v.) morphine, only i.c.v. morphine
significantly prevented the development of thermal and
mechanical hyperalgesia (Fig. 1C,F). Although i.t. mor-
phine produced some pre-emptying effects, it was statisti-
cally insignificant (Fig. 1B,E). Post-injury injection of
both i.t. and i.c.v. morphine at 30 min after nerve injury
did not produce any post-operative analgesia in the nerve-
injured mice at 7 day after injury (data not shown). Pre-
operative injection of morphine in sham-operated group
of mice had no effect on the withdrawal latencies or
thresholds observed at 7 days after sham operation (data
not shown).
Pre-injury subcutaneous (s.c.) morphine-induced analgesia 
was mediated by MOP in the supra-spinal sites
Since the above results suggest involvement of supra-spi-
nal sites for pre-emptying effects of morphine, we further
examined the contribution of µ-opioid receptors (MOP)
in the brain and spinal cord in mediating the pre-injury
systemic morphine-induced analgesic effect. As shown in
Fig. 2A,B, pre-injury s.c. morphine (10 mg/kg)-induced
analgesia was significantly blocked by pretreatment with
1 mg/kg of s.c. naloxone, a MOP antagonist. Moreover,
pre-injury s.c. morphine-induced preemptive analgesia
was blocked by pretreatment with 1 nmol of i.c.v.
naloxone, but not with 10 nmol of i.t. naloxone, suggest-
ing the involvement of supra-spinal MOPs in mediating
the systemic morphine-induced pre-emptying effects. The
s.c., i.t. and i.c.v. doses of naloxone were chosen from pre-
vious studies in mice [21].Molecular Pain 2005, 1:19 http://www.molecularpain.com/content/1/1/19
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Pre-injury morphine-induced analgesia is mediated 
through activation of the descending monoaminergic 
pathways in the spinal cord
Since the analgesic effect of systemic morphine is believed
to be largely mediated through activation of the descend-
ing monoaminergic pain inhibitory pathways in the spi-
nal cord [17], we next examined the effects of i.t.
injections of antagonists of serotonergic and
Pre-injury morphine-induced analgesia in partial sciatic nerve injury model mice Figure 1
Pre-injury morphine-induced analgesia in partial sciatic nerve injury model mice. A-F: Pre-injury single administration of s.c. (1, 
3, 10 mg/kg), and i.c.v. (0.3, 1, 3 nmol), but not i.t. (3, 10, 30 nmol), morphine prevented the development of thermal (A-C) and 
mechanical hyperalgesia (D-F) in the nerve-injured mice at 7 days following injury compared with vehicle pretreatment (Pre-
injury Morph 0). Post-injury injection of 10 mg/kg s.c. morphine (30 min after surgery) failed to prevent the development of 
thermal or mechanical hyperalgesia. 'Sham' indicates thermal paw withdrawal latencies or mechanical paw withdrawal thresh-
olds in control sham-operated mice. 'Morph' is morphine. Each data represents mean ± SE from 6–7 mice; *p < 0.05 compared 
with the group receiving vehicle as pretreatment.
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noradrenergic systems. As shown in Fig. 3A and 3B, i.t.
pretreatment with 3 nmol of methysergide, a serotonergic
antagonist, significantly blocked the pre-injury morphine-
induced pre-emptying effects. Intrathecal (i.t.) pretreat-
ment with 10 nmol of phentolamine, a noradrenergic
antagonist also blocked the post-operative analgesia pro-
duced by pre-injury administration of 10 mg/kg of s.c.
morphine. The antagonists alone had no effects in the
nerve-injured mice (data not shown). We performed fur-
ther experiments to explore whether i.t. injection of sero-
tonergic or noradrenergic agonists could produce similar
pre-emptying effects. As shown in Fig. 3C, i.t. pre-injury
injection of serotonin uptake inhibitor fluoxetine and α -2
adrenergic agonist clonidine, dose-dependently prevented
the thermal and mechanical hyperalgesia in injured mice.
The doses of methysergide and phentolamine were cho-
sen from previous reports in mice [21].
Pre-injury administration of morphine prevented nerve 
injury-induced expression of c-fos in the spinal cord
The immediate early gene c-fos is an important marker of
neuronal activity. Expression of Fos protein is rapidly
increased in the spinal cord in response to peripheral nox-
ious stimuli [22]. Induction of neuropathic pain has been
correlated with nerve injury-induced short-term as well as
long-term c-Fos expression in the spinal dorsal horn [23].
In the rat chronic constriction injury (CCI) model of neu-
ropathic pain, c-Fos expression was increased in the spinal
Involvement of supra-spinal MOPs in the pre-injury morphine-induced analgesic effects Figure 2
Involvement of supra-spinal MOPs in the pre-injury morphine-induced analgesic effects. A,B: Blockade of pre-injury morphine 
(10 mg/kg, s.c.)-induced analgesia by pretreatment with s.c. (1 mg/kg) or i.c.v. (1 nmol), but not i.t. (10 nmol), injection of the µ-
opioid receptor antagonist naloxone in thermal paw withdrawal (A) and mechanical paw pressure (B) tests. Thermal paw with-
drawal latencies (PWL) or mechanical paw withdrawal thresholds (PWT) were measured at 7 days following nerve injury. 
'Morph' is morphine. Each data represents mean ± SE from 6–7 mice; *p < 0.05 compared with the vehicle pretreatment. 'Veh' 
indicates group of mice receiving only vehicle saline before nerve injury operation.
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Involvement of descending monoaminergic pathways for the pre-injury morphine-induced analgesic effects Figure 3
Involvement of descending monoaminergic pathways for the pre-injury morphine-induced analgesic effects. A,B: Pre-injury 
morphine (10 mg/kg. s.c.)-induced analgesia in thermal paw withdrawal (A) and mechanical paw pressure (B) tests were 
blocked by i.t. pretreatment with 3 nmol of serotonergic antagonist methysergide (Meth) or 10 nmol of adrenergic antagonist 
phentolamine (Phen). C: Dose-dependent pre-emptying effects induced by pre-injury i.t. injection of adrenergic agonist cloni-
dine and serotonin uptake inhibitor fluoxetine in thermal paw withdrawal test. Thermal paw withdrawal latencies (PWL) or 
mechanical paw withdrawal thresholds (PWT) were measured 7 days following nerve injury. 'Morph' is morphine. Each data 
represents mean ± SE from 6–7 mice; *p < 0.05 compared with the group receiving vehicle as pretreatment.
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Prevention of nerve injury-induced expression of c-Fos protein in the spinal cord by pre-injury administration of morphine Figure 4
Prevention of nerve injury-induced expression of c-Fos protein in the spinal cord by pre-injury administration of morphine. 
A,B: Only a few c-Fos-positive neurons were found the spinal dorsal horn of control sham-operated mice. C: At 7 days follow-
ing peripheral nerve injury, numerous c-Fos-positive cells were observed in most dorsal horn laminas of ipsilateral side of the 
spinal cord. D: Some c-Fos-positive cells were also observed in the contralateral side. E,F: Pre-injury administration of 10 mg/
kg of s.c. morphine prevented the injury-induced expression of c-Fos in the spinal dorsal horn. G: Histogram of the number of 
c-Fos positive cells in ipsi- and contralateral sides of sham-operated (sham), nerve-injured (NI) and pre-injury morphine treated 
(Pre-morp) mice from three animals of each treatment group taking three sections from each animal. * p < 0.05 indicates sta-
tistically significant difference compared between the ipsilateral sides of sham and nerve-injured mice. # p < 0.05 indicates sig-
nificant compared between the ipsilateral sides of the nerve-injured and pre-injury morphine treated mice. Scale bar represents 
100 µm for all images.Molecular Pain 2005, 1:19 http://www.molecularpain.com/content/1/1/19
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dorsal horn with a peak increase at 3 days after injury, and
persisted for 30 days before returning to baseline level
[23]. In the present report we examined whether pre-
injury administration of morphine could prevent the c-
Fos expression in the spinal cord following partial sciatic
nerve ligation. As shown in Fig. 4C, partial sciatic nerve
ligation increased expression of c-Fos in the ipsilateral
side at 7 days after the injury compared with the ipsilateral
side of the sham-operated mice (Fig. 4A). Some increase
in c-Fos expression was also observed in the contralateral
side of nerve-injured mice (Fig. 4D), compared with the
control sham-operated mice (Fig. 4B). Pre-injury injection
of 10 mg/kg of s.c. morphine 30 min before surgery pre-
vented the injury-induced c-Fos expression in the spinal
cord dorsal horn (Fig. 4E,F). When we counted the
number of c-Fos-positive cells in the dorsal horn of the
spinal cord of these groups of mice, we found that there
was a significant increase in number of Fos-positive cells
in the ipsilateral side of nerve-injured mice compared
with the ipsilateral side of sham-operated mice at 7 days
following injury (Fig. 4G). Pre-injury administration of 10
mg/kg of s.c. morphine significantly reduced the number
of Fos-positive cells in the ipsilateral dorsal horn of nerve-
injured mice (Fig. 4G).
Pre-injury morphine, clonidine and fluoxetine prevented 
injury-induced increase in PKCγ  expression in the spinal 
dorsal horn
We also examined the effects of pre-injury administration
of morphine on expression of PKCγ  in the spinal dorsal
horn. Increased expression of PKCγ , an important compo-
nent of central sensitization, is well documented in ani-
mal models of peripheral neuropathic pain [24,25]. In the
present study we observed an increased expression of
PKCγ  in ipsilateral side of the spinal dorsal horn of partial
sciatic nerve-injured mice at 7 days following injury com-
pared with the ipsilateral side of control sham-operated
mice (Fig. 5A–D,K). Pre-injury administration of 10 mg/
kg of s.c. morphine almost completely prevented the
increase in PKCγ  expression observed following nerve
injury (Fig 5E,F,K). Pre-injury i.t. administration of cloni-
dine (30 nmol) and fluoxetine (30 nmol) also signifi-
cantly prevented the injury-induced increase in PKCγ
expression in spinal dorsal horn (Fig. 5G–J,K).
Discussion
In the present study, we demonstrated that a pre-injury
single administration of morphine could prevent devel-
opment of thermal and mechanical hyperalgesia in the
partial sciatic nerve injury model of neuropathic pain. We
further demonstrated that pre-injury morphine-induced
analgesia might be mediated through activation of the
descending monoaminergic pathways in the spinal cord.
In the present study, while pre-injury subcutaneous (s.c.)
and intracerebroventricular (i.c.v.) morphine produced
significant pre-emptying effects, intrathecal (i.t.) mor-
phine only slightly prevented the injury-induced hyperal-
gesia which was statistically insignificant. These results
suggest that the density of µ-opioid receptors (MOP) in
the spinal cord might be insufficient to produce the nec-
essary analgesic effect that could prevent the nerve injury-
induced initial barrage of neuronal stimulation, ulti-
mately leading to the development of central sensitiza-
tion. Such results might be in contrary to the observation
of strong acute analgesia by intrathecal morphine as
reported previously [18,26]. However, we speculate that
the distribution of MOP in the spinal cord is indeed suffi-
cient to produce acute analgesia but might be insufficient
to produce the necessary analgesia to prevent the nerve
injury-induced initial barrage of neuronal stimulation
compared with the supra-spinal sites, where MOPs are
densely distributed [16]. Moreover, blockade of systemic
morphine-induced preemptive analgesia by s.c. and i.c.v.,
but not i.t. naloxone further indicates the involvement of
supra-spinal MOPs in the pre-emptying effects of
morphine.
It is well known that the analgesic effect of systemic mor-
phine is largely mediated by activation of MOPs in brain-
stem nuclei such as nucleus raphe magnus (NRM) and
locus coeruleous (LC) that exert a net inhibitory effect on
nociceptive transmission through descending
monoaminergic pain inhibitory pathways in the spinal
cord [17]. The serotoninergic and noradrenergic systems
in the spinal cord also mediate the antinociception pro-
duced by intracerebroventricular (i.c.v.) injection of mor-
phine [27]. Consistent with these lines of evidence, pre-
injury systemic morphine-induced analgesia in our study
was significantly blocked by intrathecal (i.t.) pretreatment
with both serotonergic and noradrenergic antagonists.
Moreover, pre-injury i.t. injection of the serotonin uptake
inhibitor fluoxetine and the α -2 adrenergic agonist cloni-
dine produced significant analgesia, further indicating
ability of the spinal serotonergic and noradrenergic sys-
tem to produce sufficient level of pre-emptying effects. It
has been reported that both serotonergic and noradrener-
gic terminals innervate the presynaptic terminals of small
nociceptive primary afferents [28], and can inhibit neuro-
transmitter release [29].
Pre-injury administration of morphine also prevented the
injury-induced increases in expression of c-Fos and PKCγ
in the spinal cord. Induction of neuropathic pain has been
correlated with nerve injury-induced short-term as well as
long-term c-Fos expression in the spinal dorsal horn [23].
The blockade of nerve injury-induced c-Fos expression in
the spinal cord by pre-injury morphine indicates that
preemptive systemic morphine is able to prevent injury-
induced neuronal cascade that ultimately might cause
neuropathic pain. Activation of PKC in the spinal cordMolecular Pain 2005, 1:19 http://www.molecularpain.com/content/1/1/19
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Prevention of nerve injury-induced increase in PKCγ  expression in the spinal dorsal horn by pre-injury morphine Figure 5
Prevention of nerve injury-induced increase in PKCγ  expression in the spinal dorsal horn by pre-injury morphine. A,B: PKCγ  
immunoreactivity in the ipsilateral (A) and contralateral (B) sides of spinal dorsal horn of sham-operated mice. C,D: PKCγ -IR in 
the ipsilateral (C) and contralateral (D) sides of nerve-injured mice at 7 days after nerve injury. E,F: PKCγ -IR following pre-
injury administration of morphine (10 mg/kg, s.c.) in ipsilateral (E) and contralateral (F) sides of nerve-injured mice at day 7. G-
J: Pre-injury i.t. injection of clonidine (30 nmol) and fluoxetine (30 nmol) also prevented the injury-induced increase in PKCγ  
expression in spinal dorsal horn. K: Quantification of PKCγ  immunoreactive fluorescence in ipsilateral sides of sham operated 
(sham), nerve-injured (injured), pre-injury morphine (PEM), pre-injury clonidine (PEC) and pre-injury fluoxetine (PEF) treated 
mice. Quantification of staining intensity was done using Scion imaging software for Macintosh. The data were represented as 
the ratio of staining intensity between ipsilateral and contralateral sides of each section in the treatment groups. Data were 
taken from three animals of each treatment group taking three separate sections from each animal. *, # p < 0.05. The scale bar 
represents 100 µm for all images.Molecular Pain 2005, 1:19 http://www.molecularpain.com/content/1/1/19
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dorsal horn, which triggers sustained activation of N-
methyl-D-aspartate (NMDA) receptors, also serves as a
marker of central sensitization [30]. Among different iso-
forms of PKC, the γ  isoform was well studied with regard
to neuropathic pain. Increased expression of PKCγ  is well
documented in animal models of peripheral neuropathic
pain [24,25,31]. Reduced hyperalgesia was also observed
following peripheral nerve injury in mice lacking PKCγ
[32]. In the present study, we observed increased expres-
sion of PKCγ  in the spinal dorsal horn following partial
sciatic nerve injury, and pre-injury administration of mor-
phine prevented such increased expression. It has been
reported that majority of PKCγ -containing cells in the spi-
nal dorsal horn are mainly excitatory interneurons, and
does not contain the µ-opioid receptors (MOP) [33]. This
might be also one of the reasons for the ineffectiveness of
intrathecally injected morphine to produce significant
preemptive analgesia in our studies. Finally, the blockade
of injury-induced increase in PKCγ  expression by i.t. clo-
nidine and fluoxetine suggest that activation of descend-
ing monoaminergic system in spinal cord by systemic
morphine might have prevented the development of cen-
tral sensitization.
Conclusion
In conclusion, results of the present study demonstrate
that pre-injury administration of morphine could prevent
the development of peripheral nerve injury-induced neu-
ropathic pain through activation of descending pain
inhibitory mechanisms. These results may improve
management of chronic neuropathic pain by proper use
of morphine.
Methods
Animals
Male ddY mice weighing 20–25 g were used throughout
the experiments. The mice were housed in a room main-
tained at 21 ± 2°C, 55 ± 5 % relative humidity and an
automatic 12-h light/dark cycle with free access to stand-
ard laboratory diet and tap water. The animals were
adapted to the testing environment (maintained at 21 ±
2°C, 55 ± 5 % relative humidity and 12-h light/dark cycle)
by keeping them in the testing room 24 h before the
experiments. Experiments were performed during the
light phase of the cycle (10:00 – 17:00). All procedures
were approved by Nagasaki University Animal Care Com-
mittee and complied with the recommendations of Inter-
national Association for the Study of Pain [34].
Drugs and injection methods
Following drugs were purchased: morphine hydrochlo-
ride (Takeda Pharma. Co. Ltd., Japan), naloxone hydro-
chloride, methysergide maleate, phentolamine
hydrochloride, fluoxetine hydrochloride, and clonidine
hydrochloride (all from Sigma Co., St Louis, MO, USA).
All drugs were dissolved in physiological saline. Physio-
logical saline was used for control injections. The intrath-
ecal (i.t.) injections were performed free hand between
spinal L5 and L6 segments according to the method of
Hylden and Wilcox [35]. The intracerebroventricular
(i.c.v.) injections were carried out into the left lateral ven-
tricle of mice. Injections were performed using a Hamil-
ton microsyringe fitted with a 26-gauge i.c.v. needle,
according to the method of Haley and McCormick [36].
The site of injection was 2 mm caudal and 2 mm lateral to
the bregma, and 3 mm in depth from the skull surface.
Both i.t. and i.c.v. injections were given in a volume of 5
µl. The mice received the subcutaneous (s.c.) injections in
a volume of 0.1 ml/10 g body weight.
Partial ligation of sciatic nerve
Partial ligation of the sciatic nerve of mice was performed
under pentobarbital (50 mg/kg i.p.) anesthesia, following
the methods of Malmberg and Basbaum [37]. Briefly, the
common sciatic nerve of the right hind limb of mice was
exposed at high thigh level through a small incision and
dorsal 1/3 to 1/2 of the nerve thickness was tightly ligated
with a silk suture. The wound was closed with a single
muscle suture and antibiotic powder was dusted over the
wound area following surgery. Sham operation was
performed similarly except without touching the sciatic
nerve. Immediately following surgery, the animals were
kept in a soft bed cage with some food inside so that the
animals could feed themselves without difficulty in stand-
ing. The wound healed within 1–2 days and the animals
behaved normally. Experiments were carried out at 7 or
14 days post-ligation.
Hargreaves thermal paw withdrawal test
Analgesia was measured from the latency to withdrawal
evoked by exposing the right hind paw to a thermal stim-
ulus. Mice were placed under Plexiglas cages on top of a
glass sheet. The thermal stimulus (IITC Inc., Woodland
Hills, CA, USA) was positioned under the glass sheet to
focus the projection bulb exactly on the middle of plantar
surface of the animals. A mirror attached to the stimulus
permitted visualization of the undersurface of the paw.
After one hour of adaptation, paw withdrawal latencies
were measured at every 10 min interval until 60 min with
vehicle or drug pretreatment. A cut-off thermal latency of
20 s was set in order to prevent tissue damage.
Paw pressure test
Experiments were performed as described previously [38].
Briefly, mice were placed under a Plexiglas chamber on a
6 mm × 6 mm wire mesh grid floor and were allowed to
accommodate for a period of one hour. The mechanical
stimulus was then delivered onto the middle of the
plantar surface of right hind-paw using a Transducer Indi-
cator (Model 1601, IITC Inc., Woodland Hills, USA). TheMolecular Pain 2005, 1:19 http://www.molecularpain.com/content/1/1/19
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paw withdrawal thresholds were measured at every 10
min interval until 60 min with vehicle or drug pretreat-
ment. In this experiment, a cut-off pressure of 20 g was set
to avoid tissue damage.
DAB immunostaining for c-Fos
Mice were deeply anesthetized with i.p. pentobarbital and
perfused transcardially with 40 ml of 0.1 M potassium free
phosphate buffered saline (K+ free PBS, pH 7.4) followed
by 40 ml of 4% paraformaldehyde (PFA) in 0.1 M K+ free
PBS. The spinal cord between L4 – L5 segments was
removed and post-fixed in 4% PFA for 1 hour. Then, the
sample was transferred to 25% sucrose solution (in 0.1 M
K+ free PBS) overnight for cryoprotection. Next day, the
spinal cord sample was fast-frozen in cryoembedding
compound on a mixture of ethanol and dry-ice and stored
at -80°C until use. The spinal cord sample was cut as 20
µm thick transverse sections with a cryostat, thaw-
mounted on silane-coated glass slide and air dried over-
night at room temperature (RT). For c-Fos immunolabe-
ling, spinal cord sections were washed 3 times with K+ free
PBS for 5 min each then incubated in excess 100% meth-
anol with 0.1% H2O2. After 3 washings with K+ free PBS,
the sections were incubated in excess blocking buffer con-
taining 10% normal goat serum and 2% bovine serum
albumin in PBST (2% NaCl, 0.1% Triton-X 100 in K+ free
PBS) for 60 min at RT. The sections were washed and
reacted with rabbit polyclonal antibody raised against the
c-Fos protein (1:1000 in 2% BSA in PBST solution; sc-
7202, Santa Cruz Biotechnology, CA, USA) at 4°C over-
night. After thorough washings, the sections were incu-
bated with secondary antibody, biotinylated anti-rabbit
IgG (1:200 in 2% BSA in PBST solution; Vector, CA, USA)
at RT for 60 min, and subsequently with ABC complex
(Vector, CA) at RT for 60 min. The antigen-antibody reac-
tion sites were visualized by incubation with a solution
containing 0.005% 3,3'-diaminobenzidine tetrahydro-
chloride (DAB; Dojindo, Japan), 0.002% H2O2, 0.001%
nickel ammonium sulfate and 0.002% cobalt chloride in
0.1 M K+ free PBS until the black reaction products appear.
The reaction was stopped by washing with ice-cold PBS.
After 3–4 washings, the sections were cover-slipped and
visualized under a light microscope. The number of c-Fos-
positive cells in the ipsi-and contralateral sides of dorsal
horn gray mater of the spinal cord was then counted from
lamina I-VI and plotted in a bar graph.
Fluorescence immunohistochemistry for PKCγ
The spinal cord sections were prepared as described
above. For immunostaining of PKCγ , the spinal cord sec-
tions were first pre-blocked with blocking buffer contain-
ing 10% normal goat serum and 2% bovine serum
albumin in PBST. The sections were then reacted with a
rabbit polyclonal antibody raised against the γ  isoform of
protein kinase C (1:500 in 2% BSA in PBST solution; sc-
211, Santa Cruz Biotechnology, CA, USA) at 4°C over-
night. The sections were then incubated with a FITC-con-
jugated anti-rabbit IgG (1:200; Santa Cruz Biotechnology)
for 60 min at RT. The sections were washed thoroughly,
cover-slipped with Perma Fluor (Thermo Shandon, Pitts-
burgh, PA, USA) and examined under a fluorescence
microscope (Olympus, Tokyo, Japan). Quantification of
the intensity of PKCγ -positive fluorescence was then done
using Scion imaging software for Macintosh (Scion Cor-
poration, USA).
Statistical analysis
Statistical evaluations of the data were performed by com-
parison with repeated measures analysis of variance
(ANOVA) with suitable post-hoc tests. The criterion of sig-
nificance was set at p < 0.05. All results are expressed as the
mean ± SEM.
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